Emodin reverses resistance to gemcitabine in pancreatic cancer by suppressing stemness through regulation of the epithelial‑mesenchymal transition

The present study aimed to explore the effects and underlying mechanisms of emodin (Emo) on gemcitabine (GEM)-resistant pancreatic cancer. GEM-resistant SW1990 cells (SW1990/GZ) were established by successively doubling the concentration of GEM. Cell viability was measured using the CCK-8 assay and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Weitian, Wang, Jiangfeng, Hu, Yuqian, Chen, Sheng, Liu, Jinshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748633/
https://www.ncbi.nlm.nih.gov/pubmed/36545274
http://dx.doi.org/10.3892/etm.2022.11706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748633/
https://www.ncbi.nlm.nih.gov/pubmed/36545274
http://dx.doi.org/10.3892/etm.2022.11706

Ejemplares similares